The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...

The US Food and Drug Administration (FDA) has updated the labels for sodium-glucose cotransporter 2 (SGLT2) inhibitors to include the risks for ketoacidosis and serious urinary tract infections. Both ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — SGLT2 inhibitors can reduce the need for urate-lowering and flare therapies, and lower the odds of ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...

The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

Researchers from the University of Hong Kong said on Tuesday combining imaging technology with an anti-diabetic drug ...

Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT2) ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...